EVERSANA expands commercialisation portfolio with OS Therapies and Iterum Therapeutics partnerships

EVERSANA, a leading provider of global commercial services to the life sciences industry, has announced two strategic partnerships to support the US commercialisation of innovative therapies from OS Therapies Inc. and Iterum Therapeutics plc.

OS Therapies selects EVERSANA to launch OST-HER2 for paediatric osteosarcoma

OS Therapies Inc, a clinical-stage biotechnology company focused on cancer immunotherapy and antibody drug conjugates, has appointed EVERSANA to lead the US commercialisation of OST-HER2. This novel Listeria monocytogenes-based immunotherapy targets recurrent, fully resected, paediatric lung metastatic osteosarcoma – a rare and aggressive bone cancer with limited treatment options for over four decades.

OST-HER2 has received Orphan, Fast Track, and Rare Pediatric Disease Designations from the US Food and Drug Administration (FDA). A rolling Biologics License Application (BLA) submission is expected to begin in Q3 2025, with potential approval by the end of the year.

“Working with EVERSANA ensures we have the infrastructure, expertise, and agility to bring OST-HER2 to patients and families who have long awaited new options, without the need to spend significant capital building our own commercial infrastructure,” said Paul Romness, CEO of OS Therapies.

EVERSANA will deploy its end-to-end EVERSANA ONCOLOGY Commercialization model, including market access, medical affairs, field deployment, patient services, and stakeholder engagement.

Iterum Therapeutics taps EVERSANA for US launch of ORLYNVAH, the first oral penem

Iterum Therapeutics plc, a company developing next-generation antibiotics for multi-drug resistant infections, has entered into a Product Commercialization Agreement with EVERSANA for the US launch of ORLYNVAH (oral sulopenem), the first oral penem antibiotic approved for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women with limited or no alternative oral options.

The commercial launch is targeted for Q4 2025. EVERSANA will provide comprehensive services including sales, marketing, logistics, regulatory support, and medical affairs.

“By partnering with EVERSANA and leveraging their extensive commercial capabilities, we are confident we will be able to move quickly and efficiently to ensure ORLYNVAH is made available to prescribers and patients with limited or no oral options to handle hard-to-treat uncomplicated urinary tract infections (uUTI) in the community as soon as possible,” said Corey Fishman, CEO of Iterum.

EVERSANA’s commitment to innovation and patient access

These partnerships reflect EVERSANA’s commitment to accelerating access to life-changing therapies across oncology and infectious diseases. EVERSANA currently supports over 650 life sciences organisations globally, offering integrated solutions across the product lifecycle to deliver sustainable value for patients, providers, and payers.